Full-Time

Territory Business Manager

Diabetes

Updated on 5/26/2026

Deadline 4/29/27
Xeris Pharmaceuticals

Xeris Pharmaceuticals

201-500 employees

Develops ready-to-use liquid-stable injectables

Compensation Overview

$85k - $140k/yr

+ Commission + Equity

Tennessee, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Marketing
Data Analysis
Requirements
  • Bachelor’s Degree in Health Sciences, Business/Marketing, or related field
  • 2+ years of experience in field commercial positions, including but not limited to: sales representative, hospital representative, sales trainer, and marketing (Sales Representative)
  • 5+ years of experience in bioscience commercial positions, including but not limited to: sales representative, hospital representative, sales training, marketing and regional account manager (Sr. Sales Representative)
  • A valid, US State-issued driver’s license is required
  • Able to create and execute a thoughtful business plan adjusting when needed in order to meet organizational goals
  • Proficient in understanding key data and metrics and utilizing this information to improve business performance
  • Thrives in ambiguity and uncertainty; can adapt quickly in any situation and asks questions to increase depth of understanding
  • Competencies: Self-directed, Organizational skills, Verbal and Written Communication skills, Time Management, Presentation skills, Project Management skills, Problem Solving, Negotiation skills, Influencer, Adaptability
  • Working Conditions: Position may require periodic evening and weekend work, as necessary to fulfill obligations. Travel requirements will vary by territory but will minimally be 20%
  • Position requires vehicle travel, as necessary
Responsibilities
  • Deliver on corporate objectives specific to territory.
  • With RBD and internal business partner input, develop, evolve, and execute territory and account level business plans.
  • Engage RBD with timely recommendations to eliminate or minimize barriers to progress specific to marketplace trends, business opportunities and threats, competitive information, etc.
  • Leverage internal expertise to maximize field impact.
  • Work with Regional Business Directors, Channel/Trade & Market Access Teams, and Sales Representatives to develop territory-specific strategies to ensure patient access to Xeris products.
  • Manage territory budget and resource allocations to maximize return on investment.
  • Create a face to the internal and external customer that demonstrates Xeris’ commitment to bringing value and solutions to the customers and patients we serve.
  • Collaborate with peers, marketing, and training personnel to share information and implement territory initiatives/strategies.
  • Create, build, and maintain relationships and regular communications and sales efforts with physicians & other health care providers, and all others pertinent to Xeris’ business.
  • Professionally and ethically represent Xeris to external customers (including but not limited to hospitals, IDNs, individual physicians and health care providers, and local diabetes chapters) and foster their respect by demonstrating our commitment to advancing patient care and outcomes.
  • Professionally and ethically represent Xeris internally and foster professionalism within, among, and beyond the region.
  • Take responsibility for ongoing professional development to maximize effectiveness in advancing Xeris’ objectives.
  • Leverage internal training and development.
  • Refine ability to navigate complex and multi-layered accounts
  • Refine ability to effectively communicate and engage with customers while leveraging Xeris internal resources.
Desired Qualifications
  • Recent experience in bioscience and/or diabetes is highly desirable
Xeris Pharmaceuticals

Xeris Pharmaceuticals

View

Xeris Biopharma Holdings develops ready-to-use, liquid-stable injectables for serious conditions, using its XeriSol and XeriJect platforms. Their products come in prefilled syringes or devices that do not require mixing or refrigeration, enabling smaller injections and quick administration. The company differentiates itself by delivering stable, ready-to-use formulations focused on rare diseases and endocrinology, supported by a U.S.-based field force and a portfolio that includes Gvoke, Keveyis, and Recorlev. Its goal is to expand access to simple, stable injectable therapies and grow its pipeline across endocrinology, neurology, and gastroenterology through its proprietary technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

2005

Simplify Jobs

Simplify's Take

What believers are saying

  • Recorlev revenue nearly doubled to $49.8 million in Q1 2026.
  • Xeris raised 2026 revenue guidance to $380 million-$390 million after strong Q1.
  • XP-8121 remains on track for Phase 3 initiation later in 2026.

What critics are saying

  • Gvoke faces Medicare coverage pressure, keeping revenue flat at $20.8 million.
  • Recorlev faces generic litigation threats from two applicants targeting March 2040 patents.
  • XP-8121 remains pre-Phase 3, leaving Xeris dependent on current marketed products.

What makes Xeris Pharmaceuticals unique

  • Xeris builds ready-to-use liquid-stable injectables through XeriSol and XeriJect.
  • Gvoke replaces multi-step glucagon mixing with pre-filled syringe and auto-injector options.
  • Recorlev and Keveyis target rare endocrine and neuromuscular diseases with limited competition.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Xeris Pharmaceuticals who can refer or advise you

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

401(k) Company Match

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

2%
Living Vision International Ministries
May 7th, 2026
Xeris Biopharma: Q1 earnings snapshot.

Xeris Biopharma: Q1 earnings snapshot. CHICAGO (AP) - CHICAGO (AP) - Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported first-quarter net income of $2.2 million. On a per-share basis, the Chicago-based company said it had profit of 1 cent. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was breakeven on a per-share basis. The company posted revenue of $83.1 million in the period, also beating Street forecasts. Four analysts surveyed by Zacks expected $80 million. Xeris Biopharma expects full-year revenue in the range of $380 million to $390 million. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma achieves profitability with $60M adjusted EBITDA, eyes 30% growth in 2026

Xeris Biopharma achieved financial self-sustainability in 2025, reporting its first full year of net income and nearly $60 million in adjusted EBITDA. The company posted 44% revenue growth, driven by its three commercial products, with Recorlev nearly doubling its patient base to approximately 700 patients. For 2026, Xeris has issued revenue guidance of $375 million to $390 million, representing over 30% growth. The company plans to initiate a Phase III trial for XP-8121 in the second half of 2026, requiring a $25 million increase in R&D spending. Xeris filed patent infringement lawsuits against two generic drug applicants to protect Recorlev patents extending to March 2040. Management maintains peak sales expectations of $1 billion for Recorlev by 2035 and $1 billion to $3 billion for XP-8121.

Yahoo Finance
Mar 2nd, 2026
Xeris Biopharma beats Q4 estimates with $85.8M revenue, forecasts up to $390M for 2025

Chicago-based Xeris Biopharma Holdings reported fourth-quarter earnings of $11.1 million, or 6 cents per share, surpassing Wall Street expectations of 3 cents per share. Revenue reached $85.8 million, exceeding analyst forecasts of $81.4 million. For the full year, the company reported profit of $554,000 with revenue of $291.8 million. Xeris Biopharma expects full-year revenue between $375 million and $390 million. The results beat expectations across all metrics surveyed by Zacks Investment Research.

Association of Diabetes Care and Education Specialists
Aug 10th, 2025
ADCES names Katelyn O'Brien 2026 Diabetes Care and Education Specialist of the Year

I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award.

BioSpace
Mar 31st, 2025
Xeris Announces Changes to Its Board of Directors

The Board of Directors has appointed James Brady as a new director of Xeris' board to fill the vacancy.